Needham downgraded Clearside Biomedical (CLSD) to Hold from Buy with a $3 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical downgraded to Hold from Buy at JonesResearch
- Hold Rating for Clearside Biomedical Amid Strategic Uncertainty and Financial Constraints
- Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges
- Clearside Biomedical transitions all employees to consulting roles
- Clearside Biomedical to explore strategic alternatives to advance SCS platform